NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer.IC50 & Target: IC50: 0.42 μM (ERCC1-XPF).In Vitro: NSC16168 (0-50 μM) potentiates cisplatin efficacy in cancer cells.
In Vivo: NSC16168 (20 mg/kg, ip, twice daily) exhibits significant anti-tumor activity and potentiates cisplatin antitumor activity in H460 lung cancer xenografts.